Document Detail


Treatment approaches to therapy-resistant depression.
MedLine Citation:
PMID:  22297239     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Resistance to antidepressant treatment is a controversial field and therapy resistance has received a wide range of definitions. The field has suffered from a lack of consensus on how to classify treatment resistance and from the related failure to standardise clinical criteria in trials of new therapeutic approaches. A significant proportion of tricyclic antidepressant (TCA)-resistant depression results from the failure to sustain an adequate course of therapy. This can be due to either inadequate prescribing or the poor tolerability of TCAs. The majority of cases of treatment resistance, however, involve antidepressant therapy at a dose and duration that would normally be expected to be effective. In these cases, therapy may fail for many reasons. Refractory depression may occur in patients with medical conditions such as subclinical hypothyroidism, stroke and closed head injuries. Patients with alcoholism may prove refractory to treatment, as may those receiving certain medications, notably calcium channel blockers. Certain subtypes of depression, such as rapid-cycling disorder and delusional depression, also appear to be more refractory to treatment. A variety of therapeutic approaches have been applied to treatment-resistant depression but, for most of these, placebo-controlled clinical trials with substantial numbers of patients have not been conducted. Selective serotonin re-uptake inhibitors (SSRIs) may have a role to play in TCA-resistant patients as a result of their superior tolerability; monoamine oxidase inhibitors (MAOIs) also have a significant therapeutic role. ECT has an important role to play in patients who failed to respond to successive drug therapies. Of the various add-on therapies, thyroid augmentation (triiodothyronine) of antidepressant treatment has shown promise, and definite benefits have been established for lithium augmentation. Evidence has emerged to show that lithium is not only effective as an adjunct to TCA therapy, but also to the better tolerated SSRIs. However, further trials will be necessary to determine the optimal dosage and treatment duration for lithium augmentation.
Authors:
T Dinan
Related Documents :
22541039 - Vocal acoustic biomarkers of depression severity and treatment response.
22640669 - What's in a title? an assessment of whether randomized controlled trial in a title mean...
22742989 - The Örebro musculoskeletal screening questionnaire: validation of a modified primary c...
22288009 - Recognition of facial expressions in individuals with elevated levels of depressive sym...
22321579 - The relationship between anxiety sensitivity and obsessive-compulsive symptom dimensions.
19922119 - The natural history of als is changing: improved survival.
24664349 - Gastrointestinal tolerance and utilization of agave inulin by healthy adults.
20361119 - Assessing clinical and spirometric control and the intensity of the inflammatory proces...
15352149 - Efficacy and safety of long-acting risperidone in elderly patients with schizophrenia a...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of psychopharmacology (Oxford, England)     Volume:  9     ISSN:  0269-8811     ISO Abbreviation:  J. Psychopharmacol. (Oxford)     Publication Date:  1995 Jan 
Date Detail:
Created Date:  2012-02-02     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8907828     Medline TA:  J Psychopharmacol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  199-204     Citation Subset:  -    
Affiliation:
Department of Psychological Medicine, St Bartholomew's Hospital, London, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The long-term management of depression.
Next Document:  Reduction in inappropriate prevention of urinary tract infections in long-term care facilities.